NASDAQ$KRYS
Krystal Biotech Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Krystal Biotech reported financial results and operational progress for Q1 2023.
Krystal Biotech reported a net loss of $45.3 million for the first quarter of 2023. The company's cash, cash equivalents, and investments totaled $355.5 million as of March 31, 2023. Significant progress was made in commercial preparation activities for B-VEC and advancements across the pipeline.
- PDUFA date of May 19, 2023, for B-VEC.
- Presented clinical data at ARVO on topical application of B-VEC to treat ocular complications in a patient with recessive dystrophic epidermolysis bullosa under Compassionate Use Program.
- Strong balance sheet with $355.5 million in cash, cash equivalents, and investments at the end of the quarter.
- Initiated Phase 2 cohort of its KB105-02 (JADE-1) trial in the first half of 2023.
Headline financials
Revenue & EPS history
Krystal Biotech · Revenue · Quarterly
$116M
Revenue by segment
Krystal Biotech · $91.1M total across 1 segment · Q4 2024
- VYJUVEK Net Product Revenue$91.1M—100.0%
Forward guidance
Krystal Biotech anticipates several milestones in the near future, including potential FDA approval of B-VEC, initiation of clinical trials, and regulatory submissions. However, these plans are subject to various risks and uncertainties.
Tailwinds
- Potential FDA approval of B-VEC later this month.
- Plans to start an open label extension study of B-VEC in Japan in 2023 with an approval in Japan expected in early 2025.
- Plans to initiate the Phase 2 cohort of the KB105-02 (JADE-1) trial in the first half of 2023.
- Plans to file an IND for KB104 in 2023.
- Plans to initiate a Phase 1 clinical trial of KB408 for the treatment of AATD in the second half of 2023.
Headwinds
- Uncertainties associated with regulatory review of clinical trials and applications for marketing approvals.
- The availability or commercial potential of product candidates including B-VEC.
- The sufficiency of cash resources and need for additional financing.
- Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors.
- Timing of submission of the European Medicines Agency’s marketing authorization application for B-VEC and approval in the EU is uncertain.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.3%
Avg return
Earnings day
+1.8%
Avg return
5 days after
+9.5%
Avg return
30 days after
54%
19 / 35 earnings
Positive
+52.8%
Q4 2023
Best reaction
-14.0%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | +14.9% | +13.3% | |
| Q4 2025 | +4.0% | -5.3% | -6.7% | |
| Q3 2025 | +4.9% | +0.2% | +10.1% | |
| Q2 2025 | -14.0% | -11.7% | -4.3% | |
| Q1 2025 | -13.8% | -18.6% | -18.3% | |
| Q4 2024 | +12.4% | +19.3% | +19.4% | |
| Q3 2024 | -1.1% | +13.2% | +6.4% | |
| Q2 2024 | -6.9% | -5.1% | -3.1% | |
| Q1 2024 | +0.4% | -3.9% | +4.1% | |
| Q4 2023 | +52.8% | +50.7% | +59.2% | |
| Q3 2023 | -10.7% | -19.3% | -16.1% | |
| Q2 2023 | -6.7% | -4.2% | -0.2% | |
| Q1 2023 | +9.0% | +4.7% | +51.2% | |
| Q4 2022 | +4.4% | +0.7% | +2.0% | |
| Q3 2022 | +7.7% | +4.7% | +1.6% | |
| Q2 2022 | -5.2% | -3.4% | -17.1% | |
| Q1 2022 | -4.7% | +0.4% | +15.4% | |
| Q4 2021 | +2.6% | -8.2% | +7.0% | |
| Q3 2021 | -7.4% | -7.4% | +48.5% | |
| Q2 2021 | -1.6% | -6.2% | -3.2% | |
| Q1 2021 | -7.2% | -4.0% | -7.6% | |
| Q4 2020 | +6.8% | -7.8% | -2.3% | |
| Q3 2020 | +2.6% | +3.1% | +35.0% | |
| Q2 2020 | +0.5% | +6.7% | +11.7% | |
| Q1 2020 | +13.7% | +25.3% | +3.8% | |
| Q4 2019 | -0.7% | -12.0% | -12.0% | |
| Q3 2019 | +1.6% | +0.5% | +43.5% | |
| Q2 2019 | -4.0% | -3.3% | -6.2% | |
| Q1 2019 | +2.6% | +14.6% | +1.1% | |
| Q4 2018 | -4.1% | +1.9% | +55.6% | |
| Q3 2018 | -4.7% | -1.5% | +5.4% | |
| Q2 2018 | +2.7% | +1.5% | +6.1% | |
| Q1 2018 | +0.1% | +0.2% | +23.5% | |
| Q4 2017 | +5.8% | +21.2% | +2.9% | |
| Q3 2017 | +6.0% | +1.9% | +4.1% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro